tbuckley/cabot-search huggingface dataset:
Tendinopathy and osteoarthritis: a chance to kill two birds with one stone
Authors: Robert-Jan de Vos, Gerjo JVM van Osch, Sita M A Bierma-Zeinstra, Jan AN Verhaar
Journal: British Journal of Sports Medicine (2016)

Tendinopathy and idiopathic osteoarthritis (OA) are prevalent in middle-aged active individuals and represent a significant disease burden. Both disorders are associated with overloading of musculoskeletal tissues and both respond well to mechanotherapy. Other shared risk factors include genetic predisposition, obesity and specific age.1 ,2 Both disorders have a multifactorial pathogenesis.

Tendon and cartilage both consist of an extracellular matrix with mainly collagen (type I and II respectively), proteoglycans and sparse distribution of specialised cells. The key histopathological feature of tendinopathy and OA is extracellular matrix degeneration. The 2015 study on tendon structural changes in patients with diabetes in BJSM by de Jonge et al 3 points to similarities between tendinopathy and OA, which we frequently notice in our collaborative tendon and OA research group. These similarities between degenerative tendinopathy and OA may have clinical implications. Below, we would like to display some examples.

### Role of advanced glycation end products

Advanced glycation end products (AGEs) accumulate in connective tissues of patients with type 2 diabetes. De Jonge et al 3 showed more tendon structure disorganisation in individuals with …
Abstract 18906: Congenital Right Ventricular Hypertrophy Compensation is Characterized by Sustained Angiogenesis
Authors: Peter Dromparis, Gopinath Sutendra, Roxane Paulin, Joanne Zhao, Jaskiran Sandha, Ivan M Rebeyka, David B Ross, Evangelos D Michelakis, Jayan Nagendran
Journal: Circulation (2012)

The right ventricle (RV) is hypertrophied at birth and in the neonatal period. The RV regresses to a normal phenotype in the first month of life correlated with a concomitant drop PVR over that time. The RV may remain hypertrophied and compensated in response to maintained afterload in patients with congenital heart disease (CHD) for decades; whereas the hypertrophied RV acquired in adulthood from pulmonary arterial hypertension (PAH) quickly transitions to failure, and remains their primary determinant of mortality in PAH. Potentially, the transition from RV compensation to failure has been attributed to ischemia from deficient capillary density from inadequate angiogenesis in RV hypertrophy. Angiogenesis is largely regulated by the transcription factor hypoxia-inducible factor 1a (HIF1a), which governs the transcription of proangiogenic signaling effectors. Two such effectors strongly promoting angiogenesis under HIF1a regulation are vascular endothelial growth factor (VEGF) and stromal derived factor 1 (SDF1), which promote endothelial cell survival/proliferation and recruitment of CXCR4+ stem cells, respectively. We hypothesized that sustained HIF1a-driven angiogenesis maintains adequate RV vascularity in hypertrophy, thus preventing the transition from RV compensation to failure in CHD patients. The free walls of neonatal rat RVs had elevated levels of HIF1a (immunoblot and nuclear localization) compared to those of adult RVs, adult LVs, and neonatal LVs. This was associated with increased VEGF and SDF1 expression (Immunoblot and ELISA), which correlated with increased angiogenesis (matrigel assay) and CXCR4+ stem cell recruitment (Boyden chamber migration assay). Neonatal RVs had elevated expression vascular density (CD31 expression) and tissue perfusion (Lectin) compared to adult RVs, further supporting proangiogenic signaling. Human compensated RV hypertrophy myocardium from CHD patients had elevated SDF1 and CXCR4 expression compared to normal adult RV and LV myocardium (immunoblot), suggesting HIF1a driven angiogenic pathways are maintained in CHD tissues. Therapies that maintain HIF1a signaling may delay the transition from compensation to failure in adults with acquired PAH.
Tumor Volume, Nodal Status, and Metastasis in Breast Cancer in Women<xref ref-type="fn" rid="FN2">2</xref>
Authors: E N Atkinson, B W Brown, E D Montague
Journal: JNCI Journal of the National Cancer Institute (1986)

The relationship between primary tumor volume at detection, number of positive nodes, and probability of and time until first distant metastasis was examined for a group of 2,663 women with breast cancer. Time until metastasis was shown to decrease and probability of metastasis to increase as tumor volume and number of nodes increased. Either factor remained significant after correction for the other. Simple proportional hazards models were shown to be inadequate to describe the data. Graphic techniques were used to obtain nonparametric estimates of the forms of the relationships between tumor volume, nodal status, and the time course of the occurrence of metastasis. A simple calculation demonstrated that the average contribution per cell to the probability of metastasis decreased with increasing volume.
Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study
Authors: Maria Del Trigo, Sebastien Bergeron, Mathieu Bernier, Ignacio J Amat-Santos, Rishi Puri, Francisco Campelo-Parada, Omar Abdul-Jawad Altisent, Ander Regueiro, Neal Eigler, Erez Rozenfeld, Philippe Pibarot, William T Abraham, Josep Rodés-Cabau
Journal: The Lancet (2016)
Modul–A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1St-Line Maintenance Treatment of Metastatic Colorectal Cancer (Mcrc): a Signal-Seeking Approach
Authors: H. Schmoll, D. Arnold, A. De Gramont, M. Ducreux, A. Grothey, P.J. O'Dwyer, J. Tabernero, B. Bendahmane, F. Hermann, C. Ingold, C. Mancao, S. Osborne, I. Statovci, E. Van Cutsem
Journal: Annals of Oncology (2014)
Abstract 19022: Endothelial Cell Specific CD36 Deletion Reduces Uptake of Fatty Acids by the Heart
Authors: Florian Willecke, Ni-Huiping Son, Xiang Fang, Konstantinos Drosatos, Terri Pietka, Nada A Abumrad, Ira J Goldberg
Journal: Circulation (2014)

Circulating fatty acids must cross the endothelial cell (EC) barrier to supply cardiomyocytes (CM). How this occurs is unknown. Cluster of differentiation (CD) 36 is a membrane associated protein whose total body deletion leads to reduced uptake of non-esterified fatty acids by heart, skeletal muscle and adipose tissue. To determine the contribution of EC versus CM CD36 in heart lipid uptake, we floxed CD36 and created EC- and CM-specific knockout (KO) mice. CD36 mRNA was reduced &gt;50% in the heart, lung and skeletal muscle of EC-CD36 KO mice; CM-CD36 KO mice also had an ~50% reduction of CD36 mRNA levels in the heart. Both CM- and EC-specific CD36 ablation altered heart mRNA levels of glucose transport and oxidation genes (e.g. Glut1 ~2-fold increased, PDK4 ~0.5-fold decreased); these changes were similar to those found in mice with total body CD36 deletion. Loss of EC-CD36 led to increased plasma free fatty acid levels and prevented heart lipid droplet accumulation after an overnight fast (assessed by EM and oil red O staining). Lipid droplet accumulation was less affected in CM-CD36 KO hearts. To quantify the role of CD36 in the uptake of short chain vs. long chain fatty acids we simultaneously injected mice with radiolabeled [14C]hexanoic acid and [3H]oleic acid. Compared to both floxed-CD36 and CM-CD36 KO mice, plasma clearance of oleic acid was significantly delayed, and heart and quadriceps muscle uptake of oleic acid was reduced &gt;50% in EC-CD36 KO and total-CD36 KO mice. Hexanoic acid uptake was not decreased by either deletion. Therefore, CD36 in EC is needed for the accumulation of long chain fatty acids in the heart and appears to be required for movement of fatty acids across the EC barrier.
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis
Authors: Lisa Pieri, Patrizia Bonadonna, Chiara Elena, Cristina Papayannidis, Federica Irene Grifoni, Michela Rondoni, Stefania Girlanda, Marina Mauro, Diomira Magliacane, Elena Maria Elli, Maria Loredana Iorno, Maurizio Severino, Fabio Almerigogna, Federica Scarfì, Massimiliano Bonifacio, Omar Perbellini, Anna Artuso, Simona Soverini, Caterina De Benedittis, Simona Muratori, Luisa Lunardon, Vittoria Cova, Gabriele Cortellini, Alberto Bosi, Agostino Cortelezzi, Giovanni Martinelli, Massimo Triggiani, Serena Merante, Alessandro Maria Vannucchi, Roberta Zanotti
Journal: Blood (2014)
Distribution of Lyb-4.1 and Other Membrane Antigens on Murine Lymphoid Tumors&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: R C Howe, R S Nelson, K M Rogan, A Ahmed, J J Aiken, M E Dorf, J C Scherer, K W Sell, R E Humphreys
Journal: JNCI Journal of the National Cancer Institute (1979)

The distribution of membrane antigens on 6 DBA/2-derived tumors (L1210, L5178Y, P815, ABLS 11, ABLS 12, and ABLS 13) was studied by direct cytotoxicity and quantitative absorption assays. Lyb-4.1 antigen was found solely on the L1210 tumor. Iad antigens were absent from all tumors, and H-2Kd and H-2Dd antigens were present on all tumors. Immunoglobulin was adsorbed to the ascites tumors and lost after 3 days or more in tissue culture. These studies were performed to characterize the distribution of DBA/2 membrane antigens on DBA/2-derived tumors as a base line for functional and chemical studies with these tumors and with their solubilized proteins.
p21cip-1/waf-1 Deficiency Causes Deformed Nuclear Architecture, Centriole Overduplication, Polyploidy, and Relaxed Microtubule Damage Checkpoints in Human Hematopoietic Cells
Authors: Charlie Mantel, Stephen E. Braun, Suzanna Reid, Octavian Henegariu, Lisa Liu, Giao Hangoc, Hal E. Broxmeyer
Journal: Blood (1999)
Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease
Authors: Jason D. Wright, Rosa R. Cui, Anqi Wang, Ling Chen, Ana I. Tergas, William M. Burke, Cande V. Ananth, June Y. Hou, Alfred I. Neugut, Sarah M. Temkin, Y. Claire Wang, Dawn L. Hershman
Journal: JNCI Journal of the National Cancer Institute (2015)

Electric power morcellation during laparoscopic hysterectomy allows some women to undergo minimally invasive surgery but may disrupt underlying occult malignancies and increase the risk of tumor dissemination. We developed a state transition Markov cohort simulation model of the risks and benefits of hysterectomy (abdominal, laparoscopic, and laparoscopic with electric power morcellation) for women with presumed benign gynecologic disease. The model considered perioperative morbidity, mortality, risk of cancer and dissemination, and outcomes in women with an underlying malignancy. We explored the effectiveness from a societal perspective stratified by age (<40, 40–49, 50–59, and ≥60 years). Under all scenarios, modeled laparoscopic hysterectomy without morcellation was the most beneficial strategy. Laparoscopic hysterectomy with morcellation was associated with 80.83 more intraoperative complications, 199.64 fewer perioperative complications, and 241.80 fewer readmissions than abdominal hysterectomy per 10 000 women. Per 10 000 women younger than age 40 years, laparoscopic hysterectomy with morcellation was associated with 1.57 more cases of disseminated cancer and 0.97 fewer deaths than abdominal hysterectomy. The excess cases of disseminated cancer per 10 000 women with morcellation compared with abdominal hysterectomy increased with age to 47.54 per 10 000 in women age 60 years and older. Compared with abdominal hysterectomy, this resulted in 0.30 (age 40–49 years), 5.07 (age 50–59 years), and 18.14 (age 60 years and older) excess deaths per 10 000 women in the respective age groups. Laparoscopic hysterectomy without morcellation is the most beneficial approach of the three methods of hysterectomy studied. In older women, the risks of electric power morcellation may outweigh the benefits of minimally invasive hysterectomy.
On Trial: Evidence From Using Aspirin to Prevent Cancer:
Authors: Nancy Nelson
Journal: JNCI Journal of the National Cancer Institute (2015)

NEWS | 7 of 11 substantial lesions.Urologists aim to remove "index lesions" from the prostate, generally defined as largest tumors with the highest grade, and this depends on accurate spatial characterization.Barqawi and colleagues rely on transperineal mapping biopsies, which take 100 or more cores from the gland in a grid pattern.The results generate a threedimensional volumetric map of the prostate that can be viewed many ways, but the method has also been criticized as being too invasive.Pinto published promising results with fusion-guided biopsy, which combines multiparametric (MP) MRI and transrectal ultrasound.Earlier this year, in the Journal of the American Medical Association, he reported that MP-MRI picks up 30% more high-grade tumors than standard biopsies.Pinto said the finding "improved confidence in our ability to offer focal therapy to our patients, which is all predicated on our ability to see the tumor."Yet in a Journal of Clinical Oncology editorial last April, Gianluca Giannarini, M.D., from the University of Bern in Switzerland, cited a consensus position that even with MP-MRI, "predominantly anteriorly or apically located lesions cannot
Effect of the Presence and Type of Angina on Cardiovascular Events in Patients Without Known Coronary Artery Disease Referred for Elective Coronary Angiography
Authors: John P. Vavalle, Lan Shen, Samuel Broderick, Linda K. Shaw, Pamela S. Douglas
Journal: JAMA Cardiology (2016)

This study describes the characteristics of patients referred for typical, atypical, or no angina and examines the associations between angina type, pre–cardiac catheterization stress test results, and burden of coronary atherosclerosis identified on coronary angiography.
Managing Chronic Kidney Disease in Older People—Reply
Authors: Andrew S. Levey, Lesley A. Inker, Josef Coresh
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel Approaches to Advanced Breast Cancer: Bevacizumab and Lapatinib
Authors: Erica L. Mayer, Nancy U. Lin, Harold J. Burstein
Journal: Journal of the National Comprehensive Cancer Network (2007)

New biological therapies continue to emerge in breast cancer. Recent advances with anti-angiogenesis therapies and anti-HER2 therapies highlight the next generation of treatments that will be entering clinical practice. Important questions regarding these targeted treatments remain, however. There are uncertainties as to how best to integrate new drugs into existing treatment algorithms, whether to use monotherapy or combination therapy with chemotherapy, and how to manage novel side effects seen with these agents. This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual-kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer.
H3K9me3-Governed Senescence In Tumor Development and Lymphoma Treatment
Authors: Julia Kase, Jan Dörr, Yong Yu, Maja Milanovic, Sujuan Ji, Sandra Spiesicke-Wegener, Philipp Lohneis, Bernd Dörken, Soyoung Lee, Clemens A. Schmitt
Journal: Blood (2013)
Staphylococcal enterotoxin specific IgE in serum is linked to severe asthma and nasal polyposis
Authors: Peter Tomassen, Lars-Olaf Cardell, Natalie De Ruyck, Ulrike Förster, Wytske Fokkens, Philippe Gevaert, Peter Hellings, Valérie Hox, Elina Katainen, Marek Kowalski, Joaquim Mullol, Heidi Olze, Agnieszka Olzewska, Ann Reutherborg, Christine Segboer, Elina Toskala, Nicholas Van Bruaene, Cornelis Van Drunen, Thibaut Van Zele, Claus Bachert
Journal: Allergy (2011)
NIMG-22MORPHOLOGICAL RECONSTRUCTION BASED AUTOMATED SEGMENTATION OF GLIOBLASTOMA TUMOR VOLUME ON MULTI-MODAL MRI IMAGES
Authors: Sushmita Datta, Jay-Jiguang Zhu, Roy Riascos, Ponnada Narayana
Journal: Neuro-Oncology (2015)

BACKGROUND: Glioblastoma is the most aggressive brain tumor and, magnetic resonance imaging (MRI) is the most common imaging tool for brain tumor diagnosis and disease status monitoring post any intervention including craniotomy, irradiation and various chemotherapies. Tumor volume estimation using MRI is routinely used to determine responses, such as Macdonald's or RANO's criteria. Current techniques used for tumor volume measurements are manual measurements of the largest two-dimensional tumor area and they are inaccurate and operator-dependent. Automated techniques for estimating volumetric measurements are needed for minimizing human bias and to follow disease status objectively. We developed and implement automated segmentation of tumors by fusing information from multi-modal MRI. METHODS: High resolution three-dimensional (1 mm3 isotropic voxel) T2-weighted (T2), fluid attenuated inversion recovery (FLAIR), and T1-weighted (T1) pre- and post-contrast images were acquired on nine glioblastoma patients. The images were pre-processed for co-registration, skull-stripping, intensity non-uniformities correction, noise reduction, and intensity standardization. Regional maxima were obtained on T2/FLAIR images using grayscale morphological reconstruction followed by adaptive thresholding, and regional multi-modal density distribution, connectivity, and growing techniques. Enhanced region of the tumor was obtained from the T1 pre-/post-contrast images followed by the minimization of false classifications arising from enhancing vasculature. Classified regions from T2/FLAIR, and T1 pre-/post-contrast images were combined to obtain enhancing tumor component and the surrounding FLAIR changes representing vasogenic edema/tumor infiltration as the final segmentation for volumetric measurements. RESULTS: The automatic program is able to capture and calculate tumor volumes from T1 post contrast or T2/FLAIR images accurately, as judged by neuroradiologists, neurosurgeons and neuro-oncologists. Additionally, our technique performed consistently well across all the patients that we scanned without any human intervention. CONCLUSION: We developed and implemented automated technique that identifies tumor volumes precisely, improves the accuracy and efficiency of tumor status measurements significantly with minimal human bias.
Outcomes of advanced stage non-small cell lung cancer (NSCLC) patients reexposed to platinum-based chemotherapy upon progression
Authors: P. H. Souza, A. N. Rodrigues, R. Dienstmann, I. A. Small, W. Roriz, R. G. Martins, M. Zukin, C. G. Ferreira
Journal: Journal of Clinical Oncology (2006)

17136 Background: Platinum-based chemotherapy (PtCT) is the standard 1st-line treatment for advanced stage NSCLC patients. Nearly all patients (pts) that respond to 1st-line CT will relapse and some of them will be candidates for 2nd-line CT. There is no consensus definition of sensitive or resistant pts to PtCT and there are conflicting results about the relationship between response to prior PtCT and response to a 2nd-line reexposure. The aim of this study was to evaluate the outcomes of a subset of pts considered sensitive to platinum, who were reexposed to a PtCT regimen as 2nd-line CT. Methods: Based on a criterion of disease progression &gt; 6 months of completing 1st-line as a hallmark platinum-sensitivity, pts were retrospectively selected. We reviewed the outcomes of 11 advanced NSCLC pts (stages IIIB or IV) treated between Jan 2000 and Jun 2005 at 1st-line with a PtCT (cisplatin or carboplatin combined to etoposide) and who upon progression were reexposed to a regimen of Carboplatin plus etoposide. Pts were evaluated for overall (OS) and progression-free survival (PFS) after 1st- and 2nd-line CT by Kaplan-Meyer method. Results: There were 6 women (54.5%) and 5 men (45.5%). Median age was 62 (range 49–78) and adenocarcinoma was the most prevalent histology (54.5%). At 1st-line CT, 6 patients (54.5%) were stage IIIB and ECOG PS 0/1 were 36.4 and 63.6%, respectively. The median number of cycles per patient was 6 (range 2–8) at 1st-line and 4 (range 2–4) at 2nd-line treatment. With a median follow-up of 29 months, there were 4 deaths (36.5%) with a median OS of 49 months (CI 95%; 29.38–68.62). The median PFS after first-line was 17 months (IC 95%; 13.87–20.13). To date, 7 pts have progressed after 2nd-line CT with a median PFS of 8 months (IC 95%; 5.92–10.09). Conclusions: This subset of pts with longer progression-free interval (&gt; 6 months) after 1st-line PtCT seems to remain sensitive to platinum compounds upon disease progression. Despite the high proportion of stage III in our sample, based on the long DFS and OS observed, it seems that this population has a more favorable biology than the general population with NSCLC. Further studies, in particular pharmacogenetic analyses, are needed in order to better characterize and treat this population. No significant financial relationships to disclose.